Premium
ENHANCEMENT OF ANTIBODY RESPONSE AND DELAYED‐TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE
Author(s) -
DESCOTES J.,
TEDONE R.,
EVREUX J.C.
Publication year - 1988
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1988.tb00650.x
Subject(s) - thalidomide , medicine , immunology , delayed hypersensitivity , antibody , antibody response , immune system , multiple myeloma
Summary— Renewed interest in thalidomide stemmed from the suggestion by several authors that it might prove useful against immune‐related diseases. Despite interesting preliminary findings, little is actually known regarding its immunoenhancing properties in vivo . Male and female Swiss mice, aged 6–8 wk, were given 0.5 or 25 mg/kg/day of thalidomide orally for 4 wk. Various immunological parameters were then assessed. When compared to controls, mice exposed to the higher dose presented with a significantly increased thymus weight index, whereas spleen weight index remained unchanged. Anti‐sheep erythrocyte plaque‐forming cells and hemagglutinin titers were increased by 44% and 29%, respectively. Contact hypersensitivity to picryl chloride was enhanced by 62%. Finally, colloidal carbon clearance was not altered. Interestingly, the lower dose (5 mg/kg/day) exerted no effect whatsoever.